Eli Lilly and Company (LLY)
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Eli Lilly: Buying Opportunity Knocking On The Front Door Again (Rating Upgrade)
Eli Lilly (LLY) outperformed with robust Q1 results showing 56% revenue growth and an EPS of $8.55, calming the market's nerves and anxiety. LLY's market share gains in incretin analogs have plateaued near 60%, as competition with Novo Nordisk (NVO) intensifies. Foundayo's early launch challenges are nuanced, with global rollout and scaling capacity seen as promising levers for LLY through 2026.
LLY Stock Jumps After Q1 Earnings Beat, 2026 Guidance Raised
LLY jumps after crushing Q1 estimates and raising 2026 outlook, powered by surging Mounjaro and Zepbound sales and strong global demand.
Demand for Weight-Loss Drugs Drove Blockbuster Results for Eli Lilly. Its Stock Is Surging.
Eli Lilly's stock is powering higher on fresh signs of booming demand for its weight-loss drugs. Will it be enough to drive a recovery for the stock?
FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies
The Food and Drug Administration proposed excluding the active ingredients in Novo Nordisk and Eli Lilly's blockbuster obesity and diabetes medications from the list of drugs that outsourcing facilities can use for compounding. If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines unless they appear on the FDA's drug shortage list.
Compared to Estimates, Lilly (LLY) Q1 Earnings: A Look at Key Metrics
The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Eli Lilly (LLY) Beats Q1 Earnings and Revenue Estimates
Eli Lilly (LLY) came out with quarterly earnings of $8.55 per share, beating the Zacks Consensus Estimate of $7.06 per share. This compares to earnings of $3.34 per share a year ago.
Eli Lilly cemented its lead in the booming weight-loss drug market with huge sales gains for the first quarter, as focus shifts to new pills
Consumer demand for blockbusters Mounjaro and Zepbound helped offset declining prices for the drugs.
Eli Lilly stock jumps 6% after strong earnings and raised guidance
Eli Lilly reported stronger-than-expected first-quarter earnings and revenue on Thursday, driven by robust demand for its blockbuster weight-loss and diabetes drugs, prompting the company to raise its full-year guidance. The pharmaceutical giant now expects 2026 revenue to range between $82 billion and $85 billion, up from its earlier forecast of $80 billion to $83 billion.
Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket
Revenue tied to Lilly's Zepbound and Mounjaro more than doubles from the same period last year.
Eli Lilly Stock Could Rise Sharply After Earnings
Eli Lilly and Company has declined over 20% since January despite strong anticipated Q1 results and has not participated in the recent market rally. Options market positioning is extremely bearish with high implied volatility, but this may set up a bullish reversal post-earnings due to premium decay. Implied volatility is expected to drop sharply after earnings, potentially forcing market makers and put holders to unwind bearish positions, adding upward pressure to LLY shares.
Here's How Much Traders Expect Eli Lilly Stock To Move After Earnings
Eli Lilly is scheduled to report its latest quarterly earnings ahead of the opening bell Thursday, with shares seen potentially falling to their lowest level in months following the report.
